Batiraxcept is under clinical development by Aravive and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Batiraxcept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Batiraxcept overview
AVB-500 is under development for the treatment of acute myelogenous leukaemia (AML), metastatic urothelial cancer including renal pelvis cancer, ureter cancer, urinary bladder cancer, urethral cancer, uterine cancer, endometrial cancer and solid tumors including renal cancer, lung cancer, breast cancer, Zika virus infections, kidney fibrosis (IgA nephropathy) and an undisclosed cancer indication (3rd oncology), non-small cell lung cancer. The drug candidate is administered through intravenous route. The drug candidate is a fusion protein which acts by targeting growth arrest-specific protein 6 (GAS6).
See Also:
It was under development for the treatment of ovarian cancer, fallopian cancer, peritoneal cancer, pancreatic ductal carcinoma, pancreatic ductal adenocarcinoma, pancreatic cancer and clear cell renal cell carcinoma.
Aravive overview
Aravive, formerly Versartis, is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of life-threatening diseases. The company’s lead product candidates include batiraxcept (AVB-500), binds to GAS6 and prevents AXL signaling to inhibit metastasis, tumor growth and restore sensitivity to anti-cancer agents. Its product treats ovarian cancer, clear cell renal cancer, pancreatic adenocarcinoma, and fibrosis. The company partners with WuXi Biologics Limited and 3D Medicines Inc., in China, Taiwan, Hong Kong and Macau to prevent human oncological diseases. Aravive is headquartered in Houston, Texas, the US.
For a complete picture of Batiraxcept’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
